Mounjaro (tirzepatide) is a GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes and weight management. Many women wonder: can Mounjaro affect your period? Whilst menstrual changes are not listed as direct adverse effects in the MHRA-approved Summary of Product Characteristics, some women report alterations in cycle regularity, flow, and timing during treatment. These changes likely result from metabolic shifts and weight loss rather than direct hormonal effects. Understanding the relationship between Mounjaro and menstrual health helps women make informed decisions and recognise when medical advice is needed.

Can Mounjaro Affect Your Menstrual Cycle?

Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities, as confirmed by NICE Technology Appraisal guidance. Importantly, menstrual cycle disturbances are not listed as an adverse effect in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), and no causal link has been established in clinical trials.

The relationship between Mounjaro and menstrual changes reported in post-marketing experience is likely indirect rather than a direct pharmacological effect on reproductive hormones. Tirzepatide works primarily by enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptying, which collectively leads to improved glycaemic control and significant weight reduction. These metabolic improvements can have downstream effects on hormonal balance, particularly in women with insulin resistance or polycystic ovary syndrome (PCOS).

Anecdotal reports of menstrual changes include alterations in cycle length, flow heaviness, duration of bleeding, and timing of periods. Some women experience heavier or lighter periods than usual, whilst others notice their cycles becoming more regular or, conversely, more irregular during the initial months of treatment. It is important to recognise that there is no official direct link established between tirzepatide and menstrual dysfunction in clinical trials, but the metabolic shifts induced by the medication can influence reproductive hormone pathways.

Crucially, the MHRA SmPC highlights that tirzepatide reduces exposure to oral contraceptives after initiation and each dose increase. Women using oral contraceptives should use an additional barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase, or consider switching to a non-oral contraceptive method. Women experiencing significant or concerning menstrual changes should discuss these with their healthcare provider to ensure appropriate assessment and management.

Weight Loss, PCOS and Menstrual Changes on Mounjaro

The substantial weight loss achieved with Mounjaro plays a central role in explaining menstrual cycle changes, particularly in women with underlying metabolic or hormonal conditions. Adipose tissue is metabolically active and produces oestrogen through the aromatisation of androgens. Rapid weight reduction alters this hormonal milieu, which can temporarily disrupt the hypothalamic-pituitary-ovarian axis, leading to changes in menstrual patterns. This phenomenon is well documented with significant weight loss from any cause, including bariatric surgery, very low-calorie diets, and other weight-loss medications.

For women with polycystic ovary syndrome, the effects of Mounjaro on menstrual regularity can be particularly pronounced and, in many cases, beneficial. As outlined in NICE guideline NG223, PCOS is characterised by insulin resistance, hyperandrogenism, and anovulation, often resulting in irregular or absent periods. By improving insulin sensitivity and promoting weight loss, tirzepatide can help restore more regular ovulatory cycles. The NHS recognises that weight loss of just 5% can lead to significant improvements in PCOS symptoms, including menstrual regularity.

However, the transition period can be unpredictable. During initial treatment, as the body adjusts to rapid metabolic changes, menstrual cycles may become temporarily erratic, though evidence for this is limited to observational reports rather than clinical trials. Some women may experience breakthrough bleeding, missed periods, or changes in premenstrual symptoms. These changes typically stabilise as weight loss plateaus and the body reaches a new metabolic equilibrium.

Improved fertility may occur in women with PCOS as cycles normalise, which has important implications for contraceptive counselling. Women of childbearing potential should be advised about the possibility of restored ovulation and the need for reliable contraception if pregnancy is not desired. According to the MHRA SmPC, tirzepatide should be discontinued at least one month before a planned pregnancy and stopped immediately if pregnancy occurs. Additionally, women using oral contraceptives should use an additional barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase, or consider switching to a non-oral contraceptive method.

When to Seek Medical Advice About Period Changes

Whilst some menstrual changes during Mounjaro treatment may be expected as part of metabolic adjustment, certain symptoms warrant prompt medical evaluation. Women should contact their GP or healthcare provider if they experience unusually heavy bleeding that soaks through sanitary protection hourly for several consecutive hours, bleeding that lasts longer than seven days, or bleeding between periods that is persistent or heavy. According to NICE guideline NG12, postmenopausal bleeding—any vaginal bleeding occurring more than twelve months after the last menstrual period—always requires urgent investigation with referral via the suspected cancer pathway (within 2 weeks), regardless of medication use, as it may indicate endometrial pathology.

Severe pelvic pain accompanying menstrual changes, particularly if associated with fever, abnormal vaginal discharge, or pain during intercourse, should be assessed promptly to exclude pelvic inflammatory disease, ovarian cysts, or other gynaecological conditions. Similarly, if periods stop completely (amenorrhoea) for three or more consecutive months in women who previously had regular periods, or for six or more months in those with previously irregular cycles, this requires evaluation. Pregnancy should be excluded as a priority, followed by assessment for other causes of amenorrhoea, including premature ovarian insufficiency, thyroid dysfunction, or hyperprolactinaemia.

Women should also seek advice if menstrual changes are accompanied by other concerning symptoms such as unexplained weight gain despite continued Mounjaro use, significant fatigue, hair loss, galactorrhoea (breast milk production when not breastfeeding), or visual disturbances. These may indicate underlying endocrine disorders requiring investigation. According to NICE guidance on heavy menstrual bleeding (NG88), a full blood count should be offered to all women with heavy periods to assess for iron deficiency anaemia, and further investigations such as pelvic ultrasound or endometrial biopsy may be indicated depending on clinical findings and risk factors. It is important that menstrual changes are not automatically attributed to Mounjaro without appropriate clinical assessment to exclude other significant pathology.

Managing Menstrual Side Effects While Taking Mounjaro

For women experiencing menstrual changes whilst taking Mounjaro, several practical strategies can help manage symptoms whilst continuing treatment. Maintaining a menstrual diary is invaluable for tracking cycle length, flow heaviness, associated symptoms, and any patterns that emerge. This information assists healthcare providers in determining whether changes are within expected parameters or require further investigation. Mobile applications designed for menstrual tracking can simplify this process and provide useful data for clinical consultations.

If periods become heavier, ensuring adequate iron intake through diet or supplementation may help prevent iron deficiency anaemia. Iron-rich foods include red meat, dark green leafy vegetables, pulses, and fortified cereals. Women with confirmed heavy menstrual bleeding may benefit from tranexamic acid, which reduces menstrual blood loss by inhibiting fibrinolysis, or hormonal treatments as outlined in NICE guideline NG88. The levonorgestrel intrauterine system (LNG-IUS) is particularly effective and may be preferable to oral contraceptives given tirzepatide's interaction with oral hormonal contraception. If combined oral contraceptives are considered for heavy bleeding, women should be advised about the potential for reduced efficacy and the need for additional contraceptive precautions.

For those experiencing irregular cycles or breakthrough bleeding, patience is often required as the body adjusts to metabolic changes. Most menstrual irregularities associated with weight loss may settle over time as weight stabilises. However, if symptoms are significantly affecting quality of life or causing distress, a review of treatment options is appropriate. Adjusting the dose escalation schedule of Mounjaro or temporarily pausing treatment should only be considered for approved clinical indications under medical supervision, not specifically for menstrual symptoms, as there is no evidence supporting this approach.

Women should be reminded that restored fertility is possible with metabolic improvement, particularly in those with PCOS. Reliable contraception is essential if pregnancy is not planned. The MHRA SmPC advises that tirzepatide should be discontinued at least one month before a planned pregnancy and stopped immediately if pregnancy occurs. Women using oral contraceptives should use an additional barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase, or consider switching to a non-oral contraceptive method such as the LNG-IUS, implant, or injectable. The UK Teratology Information Service (UKTIS) can provide additional guidance on exposure during pregnancy. Regular follow-up with healthcare providers ensures that menstrual changes are monitored appropriately, underlying conditions are managed, and treatment with Mounjaro continues to provide metabolic benefits whilst minimising adverse effects on reproductive health.

Frequently Asked Questions